bullish
Pre-IPO SciClone Pharmaceuticals - Here Are the Strength and the Concerns
276 Views08 Feb 2021 09:32
This article analyzed SciClone Pharmaceuticals in terms of its core product Zadaxin, products in the pipeline, financial position and also include concerns and potential risks for the company.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- Industry Report - Insights on China Pet Medical Industry11 Feb 2021
- InnoCare Pharma Ltd (9969.HK) - What Attracts Both Hillhouse and Vivo Capital?10 Feb 2021
- Luye Pharma (2186.HK) - Could the Magic of Hillhouse Last Long?09 Feb 2021
- Pre-IPO SciClone Pharmaceuticals - Here Are the Strength and the Concerns08 Feb 2021
- Pre-IPO BeiGene - Would the IPO on the STAR Market Be the Last Hurrah?03 Feb 2021
- Sihuan Pharmaceutical (460 HK) - The Logic Behind the Rally of the Stock Price02 Feb 2021
- Pre-IPO Adagene Inc (ADAG US) - Advanced Technology but Still Take Time for Commercialization27 Jan 2021
x